XML 56 R43.htm IDEA: XBRL DOCUMENT v3.21.2
Fair Value of Financial Instruments - Additional Information (Details) - USD ($)
$ in Thousands
1 Months Ended 3 Months Ended 6 Months Ended
Feb. 29, 2020
Jun. 30, 2021
Jun. 30, 2020
Jun. 30, 2021
Jun. 30, 2020
Feb. 23, 2021
Dec. 31, 2020
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Fair value contingent liabilities   $ 37,559   $ 37,559     $ 0
Equity securities recognition amount   25,814 $ 517 26,852 $ 517    
Verve Therapeutics, Inc.              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Equity securities recognition amount   25,800   26,900      
Equity securities   29,300   29,300      
Verve Therapeutics, Inc. | Common Stock              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Number of shares purchased under equity method 546,970            
Guide Therapeutics, Inc. | Merger Agreement              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Fair value contingent liabilities   $ 37,600   $ 37,600   $ 36,500  
Technology Milestones | Guide Therapeutics, Inc. | Maximum | Merger Agreement | Former Stockholders and Optionholders              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Potential milestone payable in form of common stock           100,000  
Product Milestones | Guide Therapeutics, Inc. | Maximum | Merger Agreement | Former Stockholders and Optionholders              
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]              
Potential milestone payable in form of common stock           $ 220,000